Rezūm水蒸气热疗用于多病共存尿潴留及留置导尿患者
该回顾性研究纳入136例因良性前列腺增大导致反复尿潴留、被认为不适合手术的多病共存患者,在门诊行Rezūm水蒸气热疗。103例(78.6%)在中位31天后恢复自主排尿,3个月和12个月分别有93.5%和91%的患者保持无需导尿。围手术期并发症轻微,主要是血尿(4.4%)和尿路感染(3.9%)。
要点
- 多病共存留置导尿患者行Rezūm水蒸气热疗,78.6%成功拔管恢复自主排尿。
- 术后3个月和12个月分别有93.5%和91%的患者保持无需导尿。
- 围手术期并发症轻微,血尿4.4%、尿路感染3.9%,均为Clavien-Dindo 1-2级。
核心结论
- Rezūm水蒸气热疗可能成为因良性前列腺增大导致尿潴留、留置导尿且被认为手术高风险或不适合手术的多病共存患者的一种有用的微创治疗选择。
研究设计与样本
- 回顾性评估2017年11月至2021年2月在三家泌尿外科科室接受门诊水蒸气热疗的136例反复尿潴留患者,采用前列腺周围阻滞和可选镇静。
主要发现
- 平均患者年龄80.3岁(±7.8),平均前列腺体积54 ml(±27.3),治疗前平均留置导尿时间4.8个月(±6.0)。
- ASA分级II级占10%、III级占71%、IV级占19%。
- 103例(78.6%)在中位31天后恢复自主排尿。
- 成功与不成功患者在年龄、前列腺体积、留置导尿时间、注射次数和ASA评分上无显著差异。
- 平均随访6.1个月(±5.9,范围1-22个月),3个月随访77例(75%),12个月随访34例(33%);3个月和12个月分别有93.5%和91%的患者保持无需导尿。
临床怎么用
- 对于因良性前列腺增大导致尿潴留、留置导尿且手术高风险或不适合手术的多病共存患者,可考虑在门诊行Rezūm水蒸气热疗以尝试拔除导尿管。
局限性
- 回顾性设计,样本量有限,随访时间较短且随访率随时间的延长而下降(12个月仅33%),随访期间死亡率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Water vapor thermal therapy (Rezūm) is a minimally invasive treatment for benign prostatic enlargement (BPE). We report on safety and efficacy of this method for treatment of recurrent urinary retention and relief of catheter dependency owing to BPE in multimorbid patients, considered unfit for surgery. METHODS: We retrospectively evaluated 136 patients with recurrent urinary retention who underwent water vapor therapy in an ambulatory setting with periprostatic block and optional sedation between 11/2017 and 02/2021 in three urological departments. The objective was successful catheter withdrawal and continuing catheter independency after 3- and 12-months following treatment. RESULTS: Mean patient age was 80.3 years (±7.8), mean prostate volume 54 ml (±27.3), and mean catheter dependency before treatment was 4.8 months (±6.0). ASA classification was a followed: II: 10%, III: 71%, and IV: 19%. All procedures were performed successfully in an ambulatory setting. Perioperative complications were infrequent and minor (Clavien-Dindo Grade 1-2) and included haematuria in 4.4% and urinary tract infection in 3.9% of all cases. A total of 103 patients (78.6%) were able to void spontaneously after a median of 31 days. No significant differences in age, prostate volume, duration of catheter dependency, vapor injections, and ASA score were found between patients with successful or unsuccessful outcome. The mean follow-up period was 6.1 months (±5.9, range 1-22 months). A 3-month follow-up was available for 77 patients (75%) and 34 patients (33%) were followed for 12 months. After 3 and 12 months, 93.5 and 91% of patients remained catheter independent. Fifteen patients (11%) died during follow-up, with a mean overall survival of 7.7 months (±4.7). CONCLUSIONS: Water vapor therapy may prove to be a useful, minimally invasive treatment in a multimorbid population with catheter dependency after urinary retention, secondary to BPE, considered at highest risk or unfit for surgery. Future studies are warranted.
引用
- Eredics K, Wehrberger C, Henning A, et al. Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency. Prostate Cancer Prostatic Dis. 2021. PMID: 34588631. doi:10.1038/s41391-021-00462-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。